Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers
Top Cited Papers
Open Access
- 1 September 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (17), 5144-5149
- https://doi.org/10.1158/1078-0432.ccr-07-0869
Abstract
Purpose: To determine the toxicities, maximum tolerated dose (MTD) and pharmacokinetics of the recombinant immunotoxin SS1P (anti-mesothelin dsFv-PE38) in patients with mesothelin-expressing cancers.Keywords
This publication has 23 references indexed in Scilit:
- Synergistic Antitumor Activity of Taxol and Immunotoxin SS1P in Tumor-Bearing MiceClinical Cancer Research, 2006
- Immunotoxin therapy of cancerNature Reviews Cancer, 2006
- Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian CancerClinical Cancer Research, 2006
- Mesothelin Is Overexpressed in Pancreaticobiliary Adenocarcinomas but Not in Normal Pancreas and Chronic PancreatitisAmerican Journal of Clinical Pathology, 2005
- Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell MalignanciesJournal of Clinical Oncology, 2005
- MesothelinClinical Cancer Research, 2004
- Value of Mesothelin Immunostaining in the Diagnosis of MesotheliomaLaboratory Investigation, 2003
- Barriers to Drug Delivery in Solid TumorsScientific American, 1994
- Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regionsBiochemistry, 1994
- Frequent expression of the tumor antigen cak1 in squamous-cell carcinomasInternational Journal of Cancer, 1992